Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Operating Leases (2019 - 2025)

Collegium Pharmaceutical (COLL) has 7 years of Operating Leases data on record, last reported at $4.5 million in Q3 2025.

  • For Q3 2025, Operating Leases fell 23.89% year-over-year to $4.5 million; the TTM value through Sep 2025 reached $4.5 million, down 23.89%, while the annual FY2024 figure was $5.5 million, 9.55% down from the prior year.
  • Operating Leases reached $4.5 million in Q3 2025 per COLL's latest filing, down from $4.9 million in the prior quarter.
  • Across five years, Operating Leases topped out at $8.6 million in Q1 2021 and bottomed at $4.5 million in Q3 2025.
  • Average Operating Leases over 5 years is $6.7 million, with a median of $6.6 million recorded in 2023.
  • Peak YoY movement for Operating Leases: dropped 7.36% in 2024, then decreased 23.89% in 2025.
  • A 5-year view of Operating Leases shows it stood at $8.0 million in 2021, then decreased by 10.55% to $7.1 million in 2022, then fell by 13.89% to $6.1 million in 2023, then fell by 9.55% to $5.5 million in 2024, then decreased by 18.74% to $4.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $4.5 million in Q3 2025, $4.9 million in Q2 2025, and $5.2 million in Q1 2025.